{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T16:08:10Z","timestamp":1764173290825},"reference-count":10,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2006,1,1]],"date-time":"2006-01-01T00:00:00Z","timestamp":1136073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2006,1]]},"DOI":"10.1016\/j.ijantimicag.2005.09.011","type":"journal-article","created":{"date-parts":[[2005,12,16]],"date-time":"2005-12-16T12:13:23Z","timestamp":1134735203000},"page":"69-72","source":"Crossref","is-referenced-by-count":17,"title":["Trends in antimicrobial susceptibility in UK centres: the MYSTIC Programme (1997\u20132002)"],"prefix":"10.1016","volume":"27","author":[{"given":"Robert G.","family":"Masterton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip J.","family":"Turner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2005.09.011_bib1","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0732-8893(01)00318-2","article-title":"Determining the value of antimicrobial surveillance programs","volume":"41","author":"Jones","year":"2001","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2005.09.011_bib2","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0924-8579(99)00115-6","article-title":"The MYSTIC (meropenem yearly susceptibility test information collection) programme","volume":"13","author":"Turner","year":"1999","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2005.09.011_bib3","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.diagmicrobio.2004.11.013","article-title":"Trends in antimicrobial susceptibilities among bacterial pathogens isolated from patients hospitalised in European medical centres: 6-year report of the MYSTIC surveillance study (1997\u20132002)","volume":"51","author":"Turner","year":"2005","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"Suppl T2","key":"10.1016\/j.ijantimicag.2005.09.011_bib4","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/jac\/46.suppl_2.9","article-title":"MYSTIC (Meropenem Yearly Susceptibility Test Information Collection): a global overview","volume":"46","author":"Turner","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2005.09.011_bib5","unstructured":"National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial test for bacteria that grow aerobically. Document M7-A6. Wayne, PA: NCCLS; 2003."},{"key":"10.1016\/j.ijantimicag.2005.09.011_bib6","unstructured":"National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. Document M100-S13. Wayne, PA: NCCLS; 2003."},{"key":"10.1016\/j.ijantimicag.2005.09.011_bib7","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0732-8893(02)00358-9","article-title":"Potency and antimicrobial spectrum update for piperacillin\/tazobactam (2000): emphasis on its activity against resistant organism populations and generally untested species causing community-acquired respiratory tract infections","volume":"43","author":"Johnson","year":"2002","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2005.09.011_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0924-8579(02)00249-2","article-title":"Sustained activity and spectrum of selected extended-spectrum \u03b2-lactams (carbapenems and cefepime) against Enterobacter spp. and ESBL-producing Klebsiella spp.: report from the SENTRY antimicrobial surveillance program (USA, 1997\u20132000)","volume":"21","author":"Jones","year":"2003","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2005.09.011_bib9","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1046\/j.1469-0691.2003.00591.x","article-title":"The activity of meropenem and comparators against Acinetobacter strains isolated from European hospitals, 1997\u20132000","volume":"9","author":"Turner","year":"2003","journal-title":"Clin Microbiol Infect"},{"issue":"Suppl 1","key":"10.1016\/j.ijantimicag.2005.09.011_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0195-6701(03)00294-9","article-title":"Appropriate antimicrobial treatment in nosocomial infections\u2014the clinical challenges","volume":"55","author":"Masterton","year":"2003","journal-title":"J Hosp Infect"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857905002876?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857905002876?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,19]],"date-time":"2019-01-19T13:52:42Z","timestamp":1547905962000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857905002876"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,1]]}},"alternative-id":["S0924857905002876"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2005.09.011","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2006,1]]}}}